{"filings":[{"id":2106118,"accession_number":"0001104659-26-092017","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2026-08-06T20:13:48+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics Q2 net loss $106.2M; Phase 3 ACCOMPLISH program dosed first patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $106.2M in Q2 2026 vs $61.7M in Q2 2025; R&D expenses $100.1M (up from $54.7M).","Cash, equivalents and short-term investments $1.3B as of June 30, 2026, expected to fund operations through 2028.","First patients dosed in Phase 3 ACCOMPLISH-1 and -2 trials of aleniglipron for chronic weight management.","Appointed John Berrios (ex-Novo Nordisk) as Chief Commercial Officer.","Phase 1 SAD data for ACCG-2671 and initiation of MAD trial on track for Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1138330,"accession_number":"0001104659-26-075720","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2026-06-18T20:05:25+00:00","items":["5.07"],"status":"ready","headline":"Structure Therapeutics shareholders elect directors, ratify auditor, approve say-on-pay at 2026 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Ted W. Love, Raymond Stevens, Daniel G. Welch as Class III directors with >161M votes for each.","Ratified Ernst & Young as independent auditor for FY2026: 164.8M for, 20.8K against.","Advisory vote on executive compensation approved: 158.5M for, 6.2M against, 212.7K abstentions.","213.2M ordinary shares outstanding as of record date April 20, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96556,"accession_number":"0001104659-26-057226","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"Structure Therapeutics Amends Sales Agreement to Raise ATM Capacity to $400M and Reports Q1 2026 Financials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended and restated Sales Agreement with Leerink Partners and Cantor Fitzgerald to remove aggregate offering limit and filed prospectus supplement increasing ATM by $150M to $400M.","Aleniglipron Phase 2 ACCESS II achieved placebo-adjusted weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks.","Cash, cash equivalents and short-term investments totaled $1.5 billion as of March 31, 2026; received $100M upfront license fee in Q1.","FDA provided positive end-of-Phase 2 feedback; Phase 3 program for aleniglipron expected to initiate in Q3 2026.","Net loss for Q1 2026 was $76.0 million, including $11.6 million non-cash share-based compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96555,"accession_number":"0001104659-26-043425","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Structure Therapeutics appoints Matthew Lang as COO and General Counsel","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lang effective April 15, 2026; salary $560,000/yr with 40% target bonus.","Equity grant: options for 223,776 ordinary shares (74,592 ADSs), time-based RSUs for 184,614 ordinary shares, and PSUs for 46,155 ordinary shares at target.","Former Chief Legal Officer at Metsera, where he helped guide the up to $10B Pfizer acquisition; also held exec roles at Lyell, Myovant, and Gilead.","Company advancing aleniglipron into Phase 3 for obesity; Lang to support operational foundation and strategic priorities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110563,"accession_number":"0001104659-26-028023","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Positive Phase 2 data: oral GLP-1 aleniglipron achieves up to 16.3% placebo-adjusted weight loss at 44 weeks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Placebo-adjusted mean weight loss 16.3% at 180 mg and 16.0% at 240 mg (p<0.0001) at 44 weeks.","OLE study shows continued weight loss up to 16.2% at 56 weeks; no plateau observed.","Lower 2.5 mg starting dose improves tolerability; AE-related discontinuations 2-3.4% in interim OLE / body composition studies.","End-of-Phase 2 meeting with FDA scheduled Q2 2026; Phase 3 initiation on track for 2H 2026.","No drug-induced liver injury, no persistent liver enzyme elevations, no QTc prolongation across >625 participants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110562,"accession_number":"0001104659-26-020494","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics posts Q4 net income; aleniglipron up to 15.3% weight loss in Phase 2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net income $33.0M vs. net loss of $36.5M in Q4 2024; full-year net loss $141.2M.","Cash, equivalents and investments $1.4B as of Dec 31, 2025, funding through end of 2028.","Aleniglipron Phase 2 ACCESS II: placebo-adjusted weight loss up to 15.3% with 240 mg at 36 weeks.","Phase 3 for aleniglipron expected in H2 2026; topline 44-week data from ACCESS II due Q1 2026.","Oral amylin agonists: ACCG-2671 in Phase 1; ACCG-3535 to enter Phase 1 in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110561,"accession_number":"0001104659-26-000620","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Structure Therapeutics licenses GLP-1 patents to Genentech for $100M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gasherbrum Bio (Structure sub) grants non-exclusive license to Genentech/Roche for CT-996 GLP-1 RA.","Genentech pays $100M one-time non-refundable fee within 30 days; plus low single-digit royalties.","License covers patents distinct from aleniglipron; Structure's own GLP-1/dual agonist programs unaffected.","Either party may terminate for uncured material breach; Gasherbrum can terminate if GNE challenges patents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127179,"accession_number":"0001104659-25-120015","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Structure Therapeutics launches $650M follow-on offering of ADSs and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$650M from 8.46M ADSs at $65.00 and 1.54M pre-funded warrants at $64.9999.","Underwriters include Jefferies, Leerink, Goldman Sachs, Morgan Stanley; 30-day option for 1.5M additional ADSs.","Closing expected Dec 11, 2025; pre-funded warrants have 9.99% beneficial ownership limit (can increase to 19.99%).","Offering made under effective shelf registration; proceeds before underwriting discounts and expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127178,"accession_number":"0001104659-25-119095","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Structure Therapeutics reports positive Phase 2 data for oral GLP-1 aleniglipron; plans Phase 3 by mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) at 120 mg in Phase 2b ACCESS study; up to 15.3% (35.5 lbs) at 240 mg in exploratory ACCESS II.","No AE-related discontinuations when starting at 2.5 mg in OLE and body composition studies, improving tolerability vs 5 mg start.","No cases of drug-induced liver injury, persistent liver enzyme elevations, or QTc prolongation across all aleniglipron studies.","Plans to request Type B End-of-Phase 2 meeting with FDA in H1 2026; Phase 3 program initiation expected by mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127177,"accession_number":"0001104659-25-107740","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics reports Q3 net loss $65.7M; aleniglipron data on track for year-end 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $65.7M in Q3 2025 vs. $34.0M in Q3 2024; R&D expenses rose to $59.0M from $32.6M.","Cash, cash equivalents and short-term investments totaled $799.0M as of Sep 30, 2025, expected to fund operations through at least 2027.","Topline 36-week data from aleniglipron ACCESS and ACCESS II Phase 2 studies expected by year-end 2025.","Phase 1 study of oral amylin receptor agonist ACCG-2671 anticipated by year-end 2025; second amylin candidate ACCG-3535 declared.","GAAP net loss per share not disclosed; non-cash share-based compensation was $7.5M in Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143974,"accession_number":"0001104659-25-074712","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics reports Q2 net loss $61.7M; cash $786.5M; aleniglipron data on track for year-end 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $61.7M vs $26.0M YoY; R&D expenses $54.7M (up from $22.1M) due to advancing GLP-1 program.","Cash, equivalents, and short-term investments $786.5M; expected to fund operations through at least 2027.","Topline data from aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts.","Three new aleniglipron studies initiated: maintenance switching, body composition, T2DM, with enrollment Q3/Q4 2025.","ACCG-2671 (oral amylin) Phase 1 initiation planned by year-end 2025; preclinical data presented."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162258,"accession_number":"0001104659-25-062576","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Structure Therapeutics shareholders elect directors, ratify auditor at 2025 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Eric Dobmeier and Joanne Waldstreicher elected as Class II directors (133.7M and 131.4M votes for).","Ernst & Young LLP ratified as independent auditor for FY2025 (134.3M votes for).","Advisory vote on named executive officer compensation approved (115.0M for, 19.2M against).","Shareholders selected annual frequency for future say-on-pay votes (133.6M votes for 1-year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162257,"accession_number":"0001104659-25-046149","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics Q1 net loss $46.8M; cash $836.9M; aleniglipron Ph2b data expected by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $46.8M in Q1 2025 vs $26.0M in Q1 2024; R&D expenses $42.9M (up from $20.7M).","Cash, equivalents and short-term investments $836.9M as of March 31, 2025; funding through at least 2027.","Phase 2b ACCESS and ACCESS II fully enrolled; topline 36-week data for aleniglipron expected by year-end 2025.","Initiation of Phase 1 study for oral amylin agonist ACCG-2671 planned by year-end 2025; new preclinical data at ADA June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180275,"accession_number":"0001104659-25-018275","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics: aleniglipron studies fully enrolled; Q4 net loss $36.5M, cash $883.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ACCESS and ACCESS II studies fully enrolled on schedule; topline 36-week data expected by year-end 2025.","Cash, cash equivalents and short-term investments $883.5M as of Dec 31, 2024; expected to fund operations through 2027.","Net loss Q4 2024 $36.5M ($24.5M Q4 2023); FY2024 net loss $122.5M ($89.6M FY2023).","Oral amylin agonist ACCG-2671: IND-enabling activities underway; Phase 1 initiation expected by year-end 2025.","R&D expenses increased to $33.5M for Q4 2024 from $20.0M; full year $108.8M from $70.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197072,"accession_number":"0001104659-24-129378","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Structure Therapeutics selects lead oral amylin agonist ACCG-2671 for obesity; Phase 1 start by end-2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ACCG-2671 is a Dual Amylin and Calcitonin Receptor Agonist (DACRA) designed for once-daily oral dosing.","Preclinical data show cagrilintide-like efficacy with potent target engagement and favorable safety profile.","Phase 1 clinical development expected to begin by year end 2025.","Company believes ACCG-2671 could serve as backbone therapy for fixed-dose oral combinations with GLP-1 candidate GSBR-1290.","Structure is developing a series of amylin-based candidates using its GPCR structure-based drug discovery platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197071,"accession_number":"0001104659-24-117691","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics reports Q3 2024 net loss of $34M; first patients dosed in Phase 2b ACCESS obesity study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and short-term investments $915.3M; expected to fund operations through at least 2027 excluding Phase 3 registrational studies.","Net loss $34.0M for Q3 2024 vs $23.9M in Q3 2023; R&D expenses $32.6M (up from $17.5M) driven by GLP-1R program advancement.","First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity; topline data expected Q4 2025.","Oral amylin receptor agonist development candidate expected by end of 2024; GIPR candidate expected H1 2025.","ANPA-0073 (APJR agonist) Phase 2 ready; long-term toxicology studies ongoing, expected completion in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213339,"accession_number":"0001104659-24-100668","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Structure Therapeutics appoints Blai Coll as CMO, Ashley Hall as CDO; Mark Bach departs in planned succession","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Bach to depart as CMO effective Sept 18; will serve as advisor through Dec 31.","Blai Coll, previously VP of Clinical Development, promoted to CMO effective Sept 18.","Ashley Hall appointed as newly created Chief Development Officer role.","GSBR-1290 Phase 2b for obesity planned for Q4 2024.","Dr. Coll led GSBR-1290 program; Ms. Hall brings regulatory experience from Repatha."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213338,"accession_number":"0001104659-24-093434","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-08-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Structure Therapeutics appoints Angus Russell to Board, Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Angus Russell appointed Class I director effective Aug 26, 2024; term expires at 2027 annual meeting.","Russell joins Audit Committee; Ted Love, M.D. transitioned off the Audit Committee.","Granted option for 75,000 ordinary shares (25,000 ADS) vesting over 36 months.","Annual cash retainers: $45,000 for Board service plus $10,000 for Audit Committee, prorated for 2024.","Board determined Russell independent under Nasdaq standards and meets audit committee requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213337,"accession_number":"0001104659-24-087275","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics Q2 net loss $26M; cash $927M; GSBR-1290 Phase 2b on track Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 net loss $26.0M vs $23.3M in Q2 2023; R&D expenses $22.1M, G&A $11.3M.","Cash, equivalents and short-term investments $927.1M expected to fund operations through at least 2027.","GSBR-1290 Phase 2b obesity study on track to initiate in Q4 2024; Phase 2a showed 6.2% placebo-adjusted weight loss at 12 weeks.","Amylin receptor agonist development candidate expected to be selected in Q4 2024; GIPR candidate expected H1 2025.","Phase 1 trial of LTSE-2578 (LPA1R antagonist for IPF) initiated in June 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232535,"accession_number":"0001104659-24-075724","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Structure Therapeutics elects Sharon Tetlow to board; Ted Love joins audit committee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sharon Tetlow elected as Class I director for 3-year term with 117.2M votes for, 12.6M against.","Shareholders ratified Ernst & Young as independent auditor for FY2024 (129.9M for, 32k against).","Ted W. Love, M.D. appointed to Audit Committee effective June 25, 2024.","Audit Committee now consists of Sharon Tetlow, Eric Dobmeier, and Dr. Love."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232534,"accession_number":"0001104659-24-067836","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Structure Therapeutics updates risk factors and GLP-1 agonist market data in 8-K filing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Updated disclosure: six GLP-1R agonists generated ~$35.9B in 2023 sales, projected to reach $85.9B by 2027.","Added risk factors include NHP shortage, BIOSECURE Act potential impact on WuXi STA supply, and clinical trial risks.","Phase 2a obesity cohort for GSBR-1290 showed 6.2% placebo-adjusted weight loss at 12 weeks in June 2024.","Company plans to submit IND for Phase 2b chronic weight management study of GSBR-1290 in Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232533,"accession_number":"0001104659-24-067483","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Structure Therapeutics reports positive Phase 2a data for obesity drug GSBR-1290","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GSBR-1290 achieved placebo-adjusted mean weight loss of 6.2% (p<0.0001) in Phase 2a obesity study at 12 weeks.","Capsule to tablet PK study showed up to 6.9% placebo-adjusted weight loss (p<0.0001) with new tablet formulation.","67% of GSBR-1290 treated participants achieved ≥6% weight loss and 33% ≥10% loss vs 0% for placebo.","Adverse events were GI-related; discontinuations 5% in Phase 2a and 11% in PK study; no liver injury.","Phase 2b obesity study expected to begin Q4 2024 with ~300 participants using tablet formulation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232532,"accession_number":"0001104659-24-059329","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics reports Q1 net loss $26M; GSBR-1290 Phase 2a obesity data due June 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $26.0M in Q1 2024 vs $18.0M in Q1 2023; cash $436.4M funds projected operations through at least 2026.","Topline GSBR-1290 Phase 2a obesity 12-week data for 40 participants expected June 2024; Phase 2b obesity study to start Q4 2024.","R&D expenses $20.7M (+58% YoY) driven by GLP-1R franchise; G&A expenses $11.3M (+74% YoY) from public company infrastructure.","Plan to initiate first-in-human Phase 1 trial of LTSE-2578 (oral LPA1R antagonist for IPF) in June 2024.","Amylin candidate selection expected Q4 2024; GIPR candidate selection H1 2025; ANPA-0073 (APJR) Phase 1 completed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250796,"accession_number":"0001104659-24-032121","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics Q4 net loss $24.5M; cash $467.3M; Phase 2a data due Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2023 was $24.5M ($89.6M full year); compared to $11.9M in Q4 2022.","Cash and equivalents $467.3M at year-end; expected to fund operations through 2026.","Topline GSBR-1290 Phase 2a obesity data (12-week) expected latter half of Q2 2024.","Phase 2b obesity study of GSBR-1290 planned to start Q4 2024.","R&D expenses $20.0M in Q4 2023 ($70.1M full year), up from $8.4M in Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268375,"accession_number":"0001104659-23-126639","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"GSBR-1290 Phase 2a meets endpoints; significant HbA1c and weight reductions in T2DM and obesity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["HbA1c reduction: -1.01% to -1.02% placebo-adjusted at Week 12 (p≤0.008).","Weight loss: T2DM -3.26% to -3.51% placebo-adjusted at Week 12; obesity -4.74% at Week 8 (p<0.0001).","No treatment-related SAEs; 2.8% discontinuation rate due to AEs; GI events most common.","Full 12-week obesity data expected Q2 2024; Phase 2b obesity study to start H2 2024.","Toxicology studies show >100-fold safety margin; Japanese bridging study supports global plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268374,"accession_number":"0001104659-23-118241","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Structure Therapeutics reports Q3 net loss of $23.9M, advances GSBR-1290 and forms Schrödinger collaboration","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 1b study of GSBR-1290 showed up to 4.9% placebo-adjusted weight loss; no AE-related discontinuations.","Topline Phase 2a T2DM data expected December 2023; obesity cohort data H1 2024; global Phase 2b planned H2 2024.","Completed $300M private placement in October 2023; cash $205.4M at Sept 30, extending runway through 2026.","Collaboration with Schrödinger: up to $89M milestones plus low single-digit royalties on net sales.","Net loss $23.9M for Q3 2023 vs $12.4M in Q3 2022; R&D expenses increased to $17.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285522,"accession_number":"0001104659-23-105038","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Structure Therapeutics raises ~$300M in private placement for GLP-1 pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 21.6M ordinary shares and 2.4M non-voting ordinary shares at $12.49/share (~$37.47/ADS) for ~$300M gross proceeds.","Proceeds to fund oral GLP-1R agonist GSBR-1290, next-gen GLP-1/GIPR combo, oral amylin agonist, and operations through at least 2026.","Closing expected on or about Oct 3, 2023; Jefferies and Leerink act as placement agents with 6% fee.","Registration statement to be filed within 45 days of closing to register resale of shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285521,"accession_number":"0001104659-23-105027","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Structure Therapeutics GSBR-1290 Phase 1b shows 4.9% weight loss but Phase 2a obesity data delayed to H1 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1b MAD: placebo-adjusted weight loss up to 4.9% at day 28; no severe AEs or discontinuations.","Phase 2a obesity cohort data collection omission: 24 of 40 patients missing week 12 weight; new enrollment; topline now H1 2024.","Phase 2a type 2 diabetes cohort topline still on track for latter half Q4 2023.","Phase 2b studies (T2D ~500 pts, obesity ~275 pts) planned for 2024; formulation bridging study to tablets underway.","GSBR-1290 generally well-tolerated; most AEs mild GI events; no clinically meaningful liver function changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285520,"accession_number":"0001104659-23-089815","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics reports Q2 net loss $23.3M; completes Phase 2a enrollment for GSBR-1290","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.3M for Q2 2023 vs $15.5M for Q2 2022; includes $1.7M stock-based compensation.","Cash, equivalents and short-term investments of $224.6M at June 30, 2023; expected to fund operations through at least 2025.","R&D expenses $19.4M for Q2 2023 vs $10.2M in Q2 2022, driven by GLP-1R franchise advancement.","Completed enrollment in 12-week Phase 2a study of oral GLP-1 agonist GSBR-1290 (94 participants); topline data expected latter half Q4 2023.","Appointed Ted W. Love, M.D. to Board of Directors; preparations underway for global Phase 2b study in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285519,"accession_number":"0001104659-23-087873","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Appoints Ted Love, M.D. to Board; amends director compensation policy","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ted Love, M.D. appointed as Class III director and Chair of Compensation Committee effective August 3, 2023.","Board size reduced to seven directors; Love determined independent under Nasdaq listing standards.","Initial option grant for new non-employee directors increased to 75,000 ordinary shares (25,000 ADSs).","Annual option grant set at 37,500 ordinary shares (12,500 ADSs); post-termination exercise period extended for trust transfers.","Love receives initial grant of 75,000 shares vesting over 36 months plus cash retainers of $45,000 and $10,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285518,"accession_number":"0001104659-23-078719","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2023-07-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Structure Therapeutics enters three facility leases in Shanghai and South San Francisco","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Operations lease for ~22,500 sq ft in Shanghai; annual rent ~5.20M yuan (~$0.72M); term Jan 2024–Dec 2026.","Lab lease for ~8,400 sq ft in Shanghai; annual rent ~1.99M–2.12M yuan (~$0.27–0.29M); term Feb 2024–Jan 2027.","Sublease for ~11,800 sq ft in South San Francisco; annual rent ~$0.49M initial +3% annual; term Aug 2023–Aug 2027, with 4-month rent abatement.","Leases support R&D operations in China and corporate headquarters in the US."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305440,"accession_number":"0001104659-23-068028","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Structure Therapeutics dismisses PwC, engages EY as new auditor effective for FY2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed PwC as independent auditor on May 30, 2023; PwC's reports for 2021 and 2022 were unqualified.","Engaged EY as new independent auditor for fiscal year ending December 31, 2023, effective May 31, 2023.","No disagreements between Company and PwC on accounting principles, audit scope, or procedures.","Company disclosed prior material weaknesses in internal control over financial reporting (control environment, segregation of duties, ITGC).","PwC provided letter to SEC dated June 5, 2023, agreeing with Company's statements (filed as Exhibit 16.1)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305439,"accession_number":"0001104659-23-059189","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics reports Q1 2023 net loss of $18.0M; GSBR-1290 advancing to Phase 2a","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.0M for Q1 2023, compared to $13.1M in Q1 2022; non-cash stock-based comp $2.5M.","Cash, cash equivalents and short-term investments totaled $240.9M; expected to fund operations through end of 2025.","R&D expenses $13.1M (up from $8.5M) driven by GLP-1R franchise advancement and stock-based compensation.","GSBR-1290 protocol amendment submitted to FDA to transition to Phase 2a proof-of-concept study in T2DM and obesity.","Topline data from Phase 1b MAD and Phase 2a studies of GSBR-1290 expected in second half 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324847,"accession_number":"0001104659-23-039267","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics reports Q4 2022 net loss $11.9M; GSBR-1290 Phase 1b dosing complete","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed dosing of GSBR-1290 Phase 1b in healthy overweight volunteers; topline data from Phase 1b and Phase 2a expected 2H 2023.","Completed $185.3M upsized IPO in Feb 2023; net proceeds ~$166.7M; cash position $249.4M as of Feb 28, 2023.","Cash, cash equivalents and marketable securities $90.8M at Dec 31, 2022; expects to fund operations through end of 2025.","Net loss $11.9M Q4 2022 vs $13.4M Q4 2021; full year net loss $51.3M vs $38.0M in 2021.","R&D expenses $8.4M Q4 2022, $36.2M full year; G&A $4.6M Q4, $16.4M full year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324846,"accession_number":"0001104659-23-011717","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Structure Therapeutics adopts restated articles authorizing 500M ordinary shares, effective upon IPO closing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed restated memorandum and articles on Feb 3, 2023, effective Feb 7, 2023 upon IPO closing.","Authorizes 500,000,000 ordinary shares; details previously reported in Registration Statement on Form S-1.","Seventh amended and restated memorandum and articles of association filed as Exhibit 3.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}